Mycophenolate-associated gastrointestinal adverse events are common in SSc, but not severe enough to preclude its use and it may be effective in improving or stabilizing interstitial lung disease and skin involvement. PubMed, PLoS One, 2015 May 1;10(5):e0124205. (Also see Immunosuppressants)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.